These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29116995)

  • 21. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
    Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
    Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
    Dulhunty JM; Brett SJ; De Waele JJ; Rajbhandari D; Billot L; Cotta MO; Davis JS; Finfer S; Hammond NE; Knowles S; Liu X; McGuinness S; Mysore J; Paterson DL; Peake S; Rhodes A; Roberts JA; Roger C; Shirwadkar C; Starr T; Taylor C; Myburgh JA; Lipman J;
    JAMA; 2024 Aug; 332(8):629-637. PubMed ID: 38864155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
    Lee GC; Liou H; Yee R; Quan CF; Neldner K
    Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.
    Gonçalves-Pereira J; Oliveira BS; Janeiro S; Estilita J; Monteiro C; Salgueiro A; Vieira A; Gouveia J; Paulino C; Bento L; Póvoa P
    PLoS One; 2012; 7(11):e49845. PubMed ID: 23185458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
    Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M
    J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
    Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
    Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA.
    Solórzano-Santos F; Quezada-Herrera A; Fuentes-Pacheco Y; Rodríguez-Coello G; Aguirre-Morales CE; Izelo-Flores D; Muñoz-Hernández O; Miranda-Novales MG; Labra-Zamora MG
    Rev Invest Clin; 2019; 71(4):283-290. PubMed ID: 31448789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
    J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the effectiveness of two piperacillin-tazobactam molecules in the real world.
    Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME
    Int J Infect Dis; 2018 Nov; 76():91-96. PubMed ID: 30244077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.